Was Brian T. Powl’s Kura Oncology share sale under a Rule 10b5-1 plan?

Yes. The Form 4 footnote states the sale was made under a Rule 10b5-1 trading plan. The plan was adopted on December 18, 2025, indicating the transaction was pre-arranged rather than timed at the insider’s sole discretion.

What role does Brian T. Powl hold at Kura Oncology related to this Form 4?

Brian T. Powl is Kura Oncology’s Chief Commercial Officer. His position as an officer makes his equity transactions reportable on Form 4, providing transparency into his open-market sale of 10,000 common shares at $11.00 per share.

Kura Oncology (KURA) CCO sells 10,000 shares in planned trade

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Kura Oncology, Inc. Chief Commercial Officer Brian T. Powl sold 10,000 shares of common stock in an open-market transaction at $11.00 per share. After the sale, he held 173,614 shares directly. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 18, 2025.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares ($110,000)

Net Sell 1 txn

Insider Powl Brian T.

Role Chief Commercial Officer

Sold 10,000 shs ($110K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,000	$11.00	$110K

Holdings After Transaction: Common Stock — 173,614 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares sold: 10,000 shares Sale price: $11.00 per share Shares owned after sale: 173,614 shares +1 more

4 metrics

Shares sold 10,000 shares Open-market sale on May 21, 2026

Sale price $11.00 per share Open-market sale of common stock

Shares owned after sale 173,614 shares Direct holdings following transaction

Trading plan adoption date December 18, 2025 Rule 10b5-1 trading plan for this sale

Key Terms

Rule 10b5-1 trading plan, open-market sale, Form 4, Chief Commercial Officer

4 terms

Rule 10b5-1 trading plan regulatory

"The transaction ... was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: "open-market sale" for the common stock transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Chief Commercial Officer financial

"Brian T. Powl serves as Chief Commercial Officer of Kura Oncology, Inc."

A chief commercial officer (CCO) is the senior executive responsible for a company’s revenue-generating activities, including sales, marketing, pricing, customer relationships and business development. Think of the CCO as the head coach who builds the game plan to win customers and grow sales; their effectiveness affects how fast a company earns money, enters new markets and sustains profits, making the role a key signal for investors about future revenue and competitive strength.

Form 4 Insider Transactions: What Each Field Means →

05/22/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Powl Brian T.

(Last)

(First)

(Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/21/2026		S⁽¹⁾		10,000	D	$11	173,614	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2025.

	Teresa Bair, Attorney-in-fact for Brian Powl	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Kura Oncology (KURA) report for Brian T. Powl?

Kura Oncology reported that Chief Commercial Officer Brian T. Powl sold 10,000 shares of common stock. The shares were sold in an open-market transaction at $11.00 per share, according to the Form 4 insider filing details.

At what price did Kura Oncology CCO Brian T. Powl sell his shares?

Brian T. Powl sold his 10,000 Kura Oncology shares at $11.00 per share. This open-market sale was disclosed in a Form 4 filing and was executed under a previously adopted Rule 10b5-1 trading plan.

How many Kura Oncology shares does Brian T. Powl hold after this Form 4 sale?

After the reported sale, Brian T. Powl directly holds 173,614 Kura Oncology common shares. This post-transaction balance reflects the disposal of 10,000 shares in an open-market sale at $11.00 per share disclosed in the filing.